Cannabis and cannabinoid research
Can Endocannabinoids Explain CBD-Mediated Reduction in Blood Pressure? Insights from a Randomized, Placebo-Controlled, Crossover Trial.
Marko Kumric, Goran Dujic, Josip Vrdoljak, Daniela Supe Domic, Zeljko Dujic, Josko Bozic
Published: 202510.1177/25785125251392773
Abstract
Background: HYPER-H21-4 trial, a randomized, placebo-controlled, crossover trial, showed that chronic cannabidiol (CBD) supplementation reduces blood pressure (BP) in patients with primary hypertension. Given the association between the endocannabino…
Preview only. Read the full abstract at the source